Literature DB >> 20096827

Polycystic ovary syndrome (PCOS).

D Dewailly1, S Hieronimus, P Mirakian, J-N Hugues.   

Abstract

1. The Rotterdam classification should be used to define PCOS in the event of: menstrual cycle anomalies; amenorrhoea, oligomenorrhoea or long cycles, clinical and/or biochemical hyperandrogenism and ultrasound appearance of polycystic ovaries. 2. The presence of two of these three criteria is sufficient once all other diagnoses have been ruled out. 3. Diagnosis of hirsutism should not be based on the Ferriman-Gallway score. 4. The ultrasound definition of PCOS contains precise criteria that must be included in the report: presence of at least 12 follicles in each ovary measuring 2-9 mm in diameter, and/or increase in ovary size>10 ml. 5. Screening for elevated plasma LH no longer necessary. Testing for GnRH serves no purpose. 6. Routine screening for metabolic abnormalities should be carried out systematically based on weight, height and BMI, waist circumference, blood pressure and laboratory parameters: plasma glucose, triglycerides, HDL cholesterol. 7. In the case of obesity (BMI>30 kg/m(2)), oral glucose tolerance testing (OGTT) is recommended where fasting serum glucose is normal. 8. Clomiphene citrate (CC) remains the first-line therapy for ovulation induction. In patients with BMI>30, it should be preceded by improvement of metabolic status through appropriate lifestyle modifications. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096827     DOI: 10.1016/j.ando.2009.12.003

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  9 in total

1.  Paternal history of diabetes mellitus and hypertension affects the prevalence and phenotype of PCOS.

Authors:  Chen Cheng; Haolin Zhang; Yue Zhao; Rong Li; Jie Qiao
Journal:  J Assist Reprod Genet       Date:  2015-10-06       Impact factor: 3.412

2.  Polycystic diseases in visceral organs.

Authors:  Shakila Abdul-Majeed; Surya M Nauli
Journal:  Obstet Gynecol Int       Date:  2011-12-26

3.  Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk.

Authors:  Qun Yu; Jin-Bei Wang
Journal:  Biomed Res Int       Date:  2016-07-12       Impact factor: 3.411

4.  Effects of Melatonin Administration on Chemical Pregnancy Rates of Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomized Clinical Trial.

Authors:  Fataneh Mokhtari; Firouzeh Akbari Asbagh; Ozra Azmoodeh; Mahmood Bakhtiyari; Amir Almasi-Hashiani
Journal:  Int J Fertil Steril       Date:  2019-07-14

Review 5.  The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis.

Authors:  Parisa Kohnepoushi; Hojat Dehghanbanadaki; Pardis Mohammadzedeh; Maziar Nikouei; Yousef Moradi
Journal:  Cancer Cell Int       Date:  2022-03-19       Impact factor: 5.722

6.  Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India.

Authors:  Uma Sinha; Keshab Sinharay; Sudipta Saha; T Amenla Longkumer; Shuvra Neel Baul; Salil Kuamr Pal
Journal:  Indian J Endocrinol Metab       Date:  2013-03

Review 7.  Reproductive outcomes of female patients with congenital adrenal hyperplasia due to 21-hydroxylase defi ciency.

Authors:  Mouna Feki Mnif; Mahdi Kamoun; Faten Hadj Kacem; Fatma Mnif; Nadia Charfi; Basma Ben Naceur; Nabila Rekik; Mohamed Abid
Journal:  Indian J Endocrinol Metab       Date:  2013-09

8.  Endocrinal and autoimmune linkage: Evidences from a controlled study of subjects with polycystic ovarian syndrome.

Authors:  Sheetal Arora; Kiran Sinha; Sachin Kolte; Ashish Mandal
Journal:  J Hum Reprod Sci       Date:  2016 Jan-Mar

9.  Production of drug metabolites by human FMO3 in Escherichia coli.

Authors:  Gianluca Catucci; Gianfranco Gilardi; Sheila J Sadeghi
Journal:  Microb Cell Fact       Date:  2020-03-20       Impact factor: 5.328

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.